Endocrinology

Back to articles

Fracture risk increased with pioglitazone

KEY POINT

Use of pioglitazone, an oral thiazolidinedione antihyperglycemic agent, was associated with an increased risk of bone fractures in insulin-resistant, nondiabetic patients with a recent history of stroke or transient ischemic attack (TIA), suggesting that treatments to improve bone health and prevent falls may be beneficial in patients receiving the drug.

SOURCES

Viscoli CM, et al. Pioglitazone and risk for bone fracture: Safety data from a randomized clinical trial. J Clin Endocrinol Metab. 2017;102(3):914–22. https://academic.oup.com/jcem/article/102/3/914/3061916/Pioglitazone-and-Risk-for-Bone-Fracture-Safety